Western pharmaceutical companies are looking into alternative suppliers after the release of a draft U.S. legislation that is seeking to restrict a Chinese drug developer and manufacturer over national security
Western pharmaceutical companies are looking into alternative suppliers after the release of a draft U.S. legislation that is seeking to restrict a Chinese drug developer and manufacturer over national security
BofA analyst David Li lowered the firm’s price target on BeiGene to $164.30 from $179.30 and keeps a Neutral rating on the shares. Given the intense competition of PARP inhibitors
בשל תחרות חזקה ממעכבי PARP ומוצרים דומים כמו דנוסומאב ובוואציזומאב בשוק הסיני, הפירמה הורידה את תחזיות ההכנסות שלה לשנים 2024-26 והלאה.
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BeiGene (BGNE – Research Report), Alcon (ALC – Research Report) and Teladoc (TDOC – Research Report).
BeiGene (BGNE)
Bank of America Securities analyst David Li reiterated a Hold rating on BeiGene today and set a price target of $164.30. The company’s shares closed last Friday at $150.03, close to its 52-week low of $132.95.
Li has an average return of
According to TipRanks.com, Li is ranked #8624 out of 8789 analysts.
Currently, the analyst consensus on BeiGene is a Strong Buy with an average price target of $252.11, which is a 68.6% upside from current levels. In a report issued on March 27, Bernstein also assigned a Hold rating to the stock with a $161.00 price target.
See today’s best-performing stocks on TipRanks >>
Alcon (ALC)
In a report released today, Julien Ouaddour from Bank of America Securities reiterated a Hold rating on Alcon, with a price target of CHF80.00. The company’s shares closed last Friday at $84.80.
According to TipRanks.com, Ouaddour is ranked #2532 out of 8789 analysts.
Alcon has an analyst consensus of Moderate Buy, with a price target consensus of $92.08.
Teladoc (TDOC)
In a report released today, Stephanie Davis from Barclays assigned a Buy rating to Teladoc, with a price target of $25.00. The company’s shares closed last Friday at $14.49, close to its 52-week low of $13.59.
According to TipRanks.com, Davis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $20.56 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BGNE:
האנליסט עדכן את מודל הכספים של החברה כדי לכלול את הדוחות הכספיים האחרונים, שינויים במוצרים שBeiGene מפתחת, ועדכונים לגבי פעילויות המכירות שלהם.